Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression

Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Stefan Lohse, Marije B. Overdijk, Michael Dechant, Christian Kellner, Iris Nagelmeier, Andreas H. Scheel, Jeroen J.Lammerts van Bueren, Jan G.J. van de Winkel, Paul W.H.I. Parren, Matthias Peipp, Thomas Valerius^*